{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T09:30:40Z","timestamp":1768037440325,"version":"3.49.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T00:00:00Z","timestamp":1626134400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T00:00:00Z","timestamp":1626134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Bone Miner Metab"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s00774-021-01250-1","type":"journal-article","created":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T13:03:21Z","timestamp":1626181401000},"page":"1066-1075","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Clinical performance of a novel chemiluminescent enzyme immunoassay for FGF23"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4071-5372","authenticated-orcid":false,"given":"Nobuaki","family":"Ito","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuo","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachiko","family":"Kitanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ikuma","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitomi","family":"Yamagami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takehide","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Shinoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Minagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Okazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichi","family":"Ozono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiki","family":"Seino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiji","family":"Fukumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,13]]},"reference":[{"key":"1250_CR1","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s00774-015-0698-7","volume":"33","author":"S Fukumoto","year":"2015","unstructured":"Fukumoto S, Ozono K, Michigami T, Minagawa M, Okazaki R, Sugimoto T, Takeuchi Y, Matsumoto T (2015) Pathogenesis and diagnostic criteria for rickets and osteomalacia\u2014proposal by an expert panel supported by the Ministry of Health, Labour and Welfare, Japan, the Japanese Society for Bone and Mineral Research, and the Japan Endocrine Society. J Bone Miner Metab 33:467\u2013473","journal-title":"J Bone Miner Metab"},{"key":"1250_CR2","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1016\/j.bone.2006.12.062","volume":"40","author":"S Fukumoto","year":"2007","unstructured":"Fukumoto S, Yamashita T (2007) FGF23 is a hormone regulating phosphate metabolism\u2014unique biological characteristics of FGF23. Bone 40:1190\u20131195","journal-title":"Bone"},{"key":"1250_CR3","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.tem.2009.02.001","volume":"20","author":"S Fukumoto","year":"2009","unstructured":"Fukumoto S, Martin TJ (2009) Bone as an endocrine organ. Trends Endocrinol Metab 20:230\u2013236","journal-title":"Trends Endocrinol Metab"},{"key":"1250_CR4","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1056\/NEJMoa020881","volume":"348","author":"KB Jonsson","year":"2003","unstructured":"Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, Yamamoto T, Hampson G, Koshiyama H, Ljunggren O, Oba K, Yang IM, Miyauchi A, Econs MJ, Lavigne J, J\u00fcppner H (2003) Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 348:1656\u20131663","journal-title":"N Engl J Med"},{"key":"1250_CR5","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1016\/j.bone.2008.02.014","volume":"42","author":"I Endo","year":"2008","unstructured":"Endo I, Fukumoto S, Ozono K, Namba N, Tanaka H, Inoue D, Minagawa M, Sugimoto T, Yamauchi M, Michigami T, Matsumoto T (2008) Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: Proposal of diagnostic criteria using FGF23 measurement. Bone 42:1235\u20131239","journal-title":"Bone"},{"key":"1250_CR6","doi-asserted-by":"publisher","first-page":"4957","DOI":"10.1210\/jc.2002-021105","volume":"87","author":"Y Yamazaki","year":"2002","unstructured":"Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, Takeuchi Y, Fujita T, Nakahara K, Yamashita T, Fukumoto S (2002) Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets\/osteomalacia. J Clin Endocrinol Metab 87:4957\u20134960","journal-title":"J Clin Endocrinol Metab"},{"key":"1250_CR7","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s00774-005-0625-4","volume":"23","author":"N Ito","year":"2005","unstructured":"Ito N, Fukumoto S, Takeuchi Y, Yasuda T, Hasegawa Y, Takemoto F, Tajima T, Dobashi K, Yamazaki Y, Yamashita T, Fujita T (2005) Comparison of two assays for fibroblast growth factor (FGF)-23. J Bone Miner Metab 23:435\u2013440","journal-title":"J Bone Miner Metab"},{"key":"1250_CR8","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1210\/jc.2005-2105","volume":"91","author":"EA Imel","year":"2006","unstructured":"Imel EA, Peacock M, Pitukcheewanont P, Heller HJ, Ward LM, Shulman D, Kassem M, Rackoff P, Zimering M, Dalkin A, Drobny E, Colussi G, Shaker JL, Hoogendoorn EH, Hui SL, Econs MJ (2006) Sensitivity of fibroblast growth factor 23 measurements in tumour-induced osteomalacia. J Clin Endocrinol Metab 91:2055\u20132061","journal-title":"J Clin Endocrinol Metab"},{"key":"1250_CR9","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1056\/NEJMoa1714641","volume":"378","author":"TO Carpenter","year":"2018","unstructured":"Carpenter TO, Whyte MP, Imel EA, Boot AM, H\u00f6gler W, Linglart A, Padidela R, Van\u2019t Hoff W, Mao M, Chen CY, Skrinar A, Kakkis E, Martin JS, Portal AA (2018) Burosumab therapy in children with X-linked hypophosphatemia. N Engl J Med 378:1987\u20131998","journal-title":"N Engl J Med"},{"key":"1250_CR10","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00223-019-00568-3","volume":"105","author":"AA Portale","year":"2019","unstructured":"Portale AA, Carpenter TO, Brandi ML, Briot K, Cheong HI et al (2019) Continued beneficial effects of burosumab in adults with X-linked hypophosphatemia: results from a 24-week treatment continuation period after a 24-week double-blind placebo-controlled period. Calcif Tissue Int 105:271\u2013284","journal-title":"Calcif Tissue Int"},{"key":"1250_CR11","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1002\/jbmr.3475","volume":"33","author":"KL Insogna","year":"2018","unstructured":"Insogna KL, Briot K, Imel EA, Kamenick\u00fd P, Ruppe MD et al (2018) A randomised, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of Burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia: week 24 primary analysis. J Bone Miner Res 33:1383\u20131393","journal-title":"J Bone Miner Res"},{"key":"1250_CR12","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1016\/S0140-6736(19)30654-3","volume":"393","author":"EA Imel","year":"2019","unstructured":"Imel EA, Glorieux FH, Whyte MP, Munns CF, Ward LM et al (2019) Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. Lancet 393:2416\u20132427","journal-title":"Lancet"},{"key":"1250_CR13","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1002\/jbmr.4184","volume":"36","author":"Y Imanishi","year":"2021","unstructured":"Imanishi Y, Ito N, Rhee Y, Takeuchi Y, Shin CS, Takahashi Y, Onuma H, Kojima M, Kanematsu M, Kanda H, Seino Y, Fukumoto S (2021) Interim analysis of a phase 2 open-label trial assessing burosumab efficacy and safety in patients with tumour-induced osteomalacia. J Bone Miner Res 36:262\u2013270","journal-title":"J Bone Miner Res"},{"key":"1250_CR14","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1002\/jbmr.4233","volume":"36","author":"SM Jan de Beur","year":"2021","unstructured":"Jan de Beur SM, Miller PD, Weber TJ, Peacock M, Insogna K, Kumar R, Rauch F, Luca D, Cimms T, Roberts MS, San Martin J, Carpenter TO (2021) Burosumab for the treatment of tumour-induced osteomalacia. J Bone Miner Res 36:627\u2013635","journal-title":"J Bone Miner Res"},{"key":"1250_CR15","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s00223-017-0307-y","volume":"101","author":"JC Souberbielle","year":"2017","unstructured":"Souberbielle JC, Pri\u00e9 D, Piketty ML, Rothenbuhler A, Delanaye P, Chanson P, Cavalier E (2017) Evaluation of a new fully automated assay for plasma intact FGF23. Calcif Tissue Int 101:510\u2013518","journal-title":"Calcif Tissue Int"},{"key":"1250_CR16","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1007\/s00198-020-05362-8","volume":"31","author":"E Cavalier","year":"2020","unstructured":"Cavalier E, Lukas P, Bottani M, Aarsand AK, Ceriotti F, Co\u015fkun A, D\u00edaz-Garz\u00f3n J, Fern\u00e0ndez-Calle P, Guerra E, Locatelli M, Sandberg S, Carobene A (2020) European biological variation study (EuBIVAS): within- and between-subject biological variation estimates of \u03b2-isomerized C-terminal telopeptide of type I collagen (\u03b2-CTX), N-terminal propeptide of type I collagen (PINP), osteocalcin, intact fibroblast growth factor 23 and uncarboxylated-unphosphorylated matrix-Gla protein-a cooperation between the EFLM Working Group on Biological Variation and the International Osteoporosis Foundation-International Federation of Clinical Chemistry Committee on bone metabolism. Osteoporos Int 31:1461\u20131470","journal-title":"Osteoporos Int"},{"key":"1250_CR17","doi-asserted-by":"publisher","first-page":"641543","DOI":"10.3389\/fendo.2021.641543","volume":"12","author":"MR Laurent","year":"2021","unstructured":"Laurent MR, De Schepper J, Trouet D, Godefroid N, Boros E, Heinrichs C, Bravenboer B, Velkeniers B, Lammens J, Harvengt P, Cavalier E, Kaux JF, Lombet J, De Waele K, Verroken C, van Hoeck K, Mortier GR, Levtchenko E, Vande Walle J (2021) IConsensus recommendations for the diagnosis and management of x-linked hypophosphatemia in Belgium. Front Endocrinol (Lausanne) 12:641543","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1250_CR18","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s00774-011-0306-4","volume":"30","author":"Y Shimizu","year":"2012","unstructured":"Shimizu Y, Fukumoto S, Fujita T (2012) Evaluation of a new automated chemiluminescence immunoassay for FGF23. J Bone Miner Metab 30:217\u2013221","journal-title":"J Bone Miner Metab"},{"key":"1250_CR19","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.cca.2014.03.022","volume":"433","author":"Z Su","year":"2014","unstructured":"Su Z, Narla SN, Zhu Y (2014) 25-Hydroxyvitamin D: analysis and clinical application. Clin Chim Acta 433:200\u2013205","journal-title":"Clin Chim Acta"},{"key":"1250_CR20","unstructured":"Website of StataCorp LLC. https:\/\/www.stata.com\/stata12\/"},{"key":"1250_CR21","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1177\/0004563215608875","volume":"53","author":"K Ichihara","year":"2016","unstructured":"Ichihara K, Yomamoto Y, Hotta T, Hosogaya S, Miyachi H, Itoh Y, Ishibashi M, Kang D (2016) Committee on common reference intervals, Japan Society of Clinical Chemistry. Collaborative derivation of reference intervals for major clinical laboratory tests in Japan. Ann Clin Biochem 53:347\u2013356","journal-title":"Ann Clin Biochem"},{"key":"1250_CR22","first-page":"1117","volume":"112","author":"T Tanaka","year":"2008","unstructured":"Tanaka T, Yamashita A, Ichihara K (2008) Reference intervals of clinical tests in children determined by a latent reference value extraction method. J Jpn Pediatric Assoc 112:1117\u20131132","journal-title":"J Jpn Pediatric Assoc"},{"key":"1250_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00774-016-0805-4","volume":"35","author":"R Okazaki","year":"2017","unstructured":"Okazaki R, Ozono K, Fukumoto S, Inoue D, Yamauchi M, Minagawa M, Michigami T, Takeuchi Y, Matsumoto T, Sugimoto T (2017) Assessment criteria for vitamin D deficiency\/insufficiency in Japan: proposal by an expert panel supported by the Research Program of Intractable Diseases, Ministry of Health, Labour and Welfare, Japan, the Japanese Society for Bone and Mineral Research and the Japan Endocrine Society [Opinion]. J Bone Miner Metab 35:1\u20135","journal-title":"J Bone Miner Metab"},{"key":"1250_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1507\/endocrj.EJ16-0548","volume":"64","author":"R Okazaki","year":"2017","unstructured":"Okazaki R, Ozono K, Fukumoto S, Inoue D, Yamauchi M, Minagawa M, Michigami T, Takeuchi Y, Matsumoto T, Sugimoto T (2017) Assessment criteria for vitamin D deficiency\/insufficiency in Japan\u2014proposal by an expert panel supported by Research Program of Intractable Diseases, Ministry of Health, Labour and Welfare, Japan, The Japanese Society for Bone and Mineral Research and The Japan Endocrine Society [Opinion]. Endocr J 64:1\u20136","journal-title":"Endocr J"},{"key":"1250_CR25","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1007\/s00520-012-1474-z","volume":"20","author":"MP Mak","year":"2012","unstructured":"Mak MP, da e Costa Silva VT, Martin RM, Lerario AM, Yu L, Hoff PM, de Castro G (2012) Advanced prostate cancer as a cause of oncogenic osteomalacia: an underdiagnosed condition. Support Care Cancer 20:2195\u20132197","journal-title":"Support Care Cancer"},{"key":"1250_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2014-206590","author":"SB Latifyan","year":"2014","unstructured":"Latifyan SB, Vanhaeverbeek M, Klastersky J (2014) Tumour-associated osteomalacia and hypoglycemia in a patient with prostate cancer: is Klotho involved? BMJ Case Rep. https:\/\/doi.org\/10.1136\/bcr-2014-206590","journal-title":"BMJ Case Rep"},{"key":"1250_CR27","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1007\/s00223-011-9527-8","volume":"89","author":"I Ramon","year":"2011","unstructured":"Ramon I, Kleynen P, Valsamis J, Body JJ, Karmali R (2011) Hypophosphatemia related to paraneoplastic Cushing syndrome in prostate cancer: cure after bilateral adrenalectomy. Calcif Tissue Int 89:442\u2013445","journal-title":"Calcif Tissue Int"},{"key":"1250_CR28","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.2337\/dc09-0209","volume":"32","author":"L Lu","year":"2009","unstructured":"Lu L, Yu Z, Pan A, Hu FB, Franco OH, Li H, Li X, Yang X, Chen Y, Lin X (2009) Plasma 25-hydroxyvitamin D concentration and metabolic syndrome among middle-aged and elderly Chinese individuals. Diabetes Care 32:1278\u20131283","journal-title":"Diabetes Care"},{"key":"1250_CR29","doi-asserted-by":"publisher","first-page":"19713","DOI":"10.1038\/s41598-019-56297-y","volume":"9","author":"J Wei","year":"2019","unstructured":"Wei J, Zhu A, Ji JS (2019) A Comparison study of vitamin D deficiency among older adults in China and the United States. Sci Rep 9:19713","journal-title":"Sci Rep"},{"key":"1250_CR30","doi-asserted-by":"publisher","DOI":"10.1177\/2309499019877517","author":"T Niikura","year":"2019","unstructured":"Niikura T, Oe K, Sakai Y, Iwakura T, Fukui T, Nishimoto H, Hayashi S, Matsumoto T, Matsushita T, Maruo A, Yagata Y, Kishimoto K, Sakurai A, Kuroda R (2019) Insufficiency and deficiency of vitamin D in elderly patients with fragility fractures of the hip in the Japanese population. J Orthop Surg (Hong Kong). https:\/\/doi.org\/10.1177\/2309499019877517","journal-title":"J Orthop Surg (Hong Kong)"},{"key":"1250_CR31","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1210\/jc.2004-1039","volume":"90","author":"SL Ferrari","year":"2005","unstructured":"Ferrari SL, Bonjour JP, Rizzoli RJ (2005) Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. Clin Endocrinol Metab 90:1519\u20131524","journal-title":"Clin Endocrinol Metab"},{"key":"1250_CR32","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s00774-007-0779-3","volume":"25","author":"N Ito","year":"2007","unstructured":"Ito N, Fukumoto S, Takeuchi Y, Takeda S, Suzuki H, Yamashita T, Fujita T (2007) Effect of acute changes of serum phosphate on fibroblast growth factor (FGF)23 levels in humans. J Bone Miner Metab 25:419\u2013422","journal-title":"J Bone Miner Metab"},{"key":"1250_CR33","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/S0140-6736(05)67569-1","volume":"366","author":"DM Jackman","year":"2005","unstructured":"Jackman DM, Johnson BE (2005) Small-cell lung cancer. Lancet 366:1385\u20131396","journal-title":"Lancet"},{"key":"1250_CR34","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1177\/1066896915617828","volume":"24","author":"A Sauder","year":"2016","unstructured":"Sauder A, Wiernek S, Dai X, Pereira R, Yudd M, Patel C, Golden A, Ahmed S, Choe J, Chang V, Sender S, Cai D (2016) FGF23-associated tumour-induced osteomalacia in a patient with small cell carcinoma: a case report and regulatory mechanism study. Int J Surg Pathol 24:116\u2013120","journal-title":"Int J Surg Pathol"},{"key":"1250_CR35","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nrurol.2014.21","volume":"11","author":"R Nadal","year":"2014","unstructured":"Nadal R, Schweizer M, Kryvenko ON, Epstein JI, Eisenberger MA (2014) Small cell carcinoma of the prostate. Nat Rev Urol 11:213\u2013219","journal-title":"Nat Rev Urol"},{"key":"1250_CR36","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1210\/jcem-24-12-1331","volume":"24","author":"RE Randall Jr","year":"1964","unstructured":"Randall RE Jr, Lirenman DS (1964) Hypocalcemia and hypophosphatemia accompanying osteoblastic metastases. J Clin Endocrinol Metab 24:1331\u20131333","journal-title":"J Clin Endocrinol Metab"},{"key":"1250_CR37","doi-asserted-by":"publisher","first-page":"275","DOI":"10.7326\/0003-4819-93-2-275","volume":"93","author":"KW Lyles","year":"1980","unstructured":"Lyles KW, Berry WR, Haussler M, Harrelson JM, Drezner MK (1980) Hypophosphatemic osteomalacia: association with prostatic carcinoma. Ann Intern Med 93:275\u2013278","journal-title":"Ann Intern Med"},{"key":"1250_CR38","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/0090-4295(83)90129-2","volume":"21","author":"UM Kabadi","year":"1983","unstructured":"Kabadi UM (1983) Osteomalacia associated with prostatic cancer and osteoblastic metastases. Urology 21:65\u201367","journal-title":"Urology"},{"key":"1250_CR39","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1111\/j.1532-5415.1993.tb06765.x","volume":"41","author":"CT McMurtry","year":"1993","unstructured":"McMurtry CT, Godschalk M, Malluche HH, Geng Z, Adler RA (1993) Oncogenic osteomalacia associated with metastatic prostate carcinoma: case report and review of the literature. J Am Geriatr Soc 41:983\u2013985","journal-title":"J Am Geriatr Soc"},{"key":"1250_CR40","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1159\/000282746","volume":"55","author":"H Nakahama","year":"1995","unstructured":"Nakahama H, Nakanishi T, Uno H, Takaoka T, Taji N, Uyama O, Kitada O, Sugita M, Miyauchi A, Sugishita T, Fujita T (1995) Prostate cancer-induced oncogenic hypophosphatemic osteomalacia. Urol Int 55:38\u201340","journal-title":"Urol Int"},{"key":"1250_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bone.2004.09.017","volume":"36","author":"RC Pelger","year":"2005","unstructured":"Pelger RC, Lycklama A, Nijeholt GA, Papapoulos SE, Hamdy NA (2005) Severe hypophosphatemic osteomalacia in hormone-refractory prostate cancer metastatic to the skeleton: natural history and pitfalls in management. Bone 36:1\u20135","journal-title":"Bone"},{"key":"1250_CR42","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1053\/j.ajkd.2007.07.031","volume":"50","author":"CL Cotant","year":"2007","unstructured":"Cotant CL, Rao PS (2007) Elevated fibroblast growth factor 23 in a patient with metastatic prostate cancer and hypophosphatemia. Am J Kidney Dis 50:1033\u20131036","journal-title":"Am J Kidney Dis"}],"container-title":["Journal of Bone and Mineral Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-021-01250-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00774-021-01250-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-021-01250-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,13]],"date-time":"2021-11-13T04:44:35Z","timestamp":1636778675000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00774-021-01250-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,13]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["1250"],"URL":"https:\/\/doi.org\/10.1007\/s00774-021-01250-1","relation":{},"ISSN":["0914-8779","1435-5604"],"issn-type":[{"value":"0914-8779","type":"print"},{"value":"1435-5604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,13]]},"assertion":[{"value":"16 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Informed consent was obtained from all individuals included in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"This study was approved by the ethical review board of the six investigational sites.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}